US6764697B1
(en)
*
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5160744A
(en)
*
|
1991-06-27 |
1992-11-03 |
Alza Corporation |
Verapmil therapy
|
GB9117361D0
(en)
*
|
1991-08-12 |
1991-09-25 |
Euro Celtique Sa |
Oral dosage form
|
FI93924C
(fi)
*
|
1991-09-17 |
1995-06-26 |
Martti Lauri Antero Marvola |
Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
|
US5422122A
(en)
*
|
1992-08-04 |
1995-06-06 |
Eurand America, Incorporated |
Controlled release potassium chloride tablet
|
ATE219933T1
(de)
*
|
1992-09-18 |
2002-07-15 |
Yamanouchi Pharma Co Ltd |
Hydrogelzubereitung mit verzögerter freisetzung
|
ATE195252T1
(de)
*
|
1993-04-23 |
2000-08-15 |
Novartis Erfind Verwalt Gmbh |
Wirkstoffabgabevorrichtung mit gesteuerter freigabe
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US6096339A
(en)
*
|
1997-04-04 |
2000-08-01 |
Alza Corporation |
Dosage form, process of making and using same
|
US6919373B1
(en)
*
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
EP1782798A3
(fr)
|
1996-11-25 |
2008-05-21 |
Alza Corporation |
Forme posologique à libération de dose croissante
|
DK0946151T3
(da)
*
|
1996-11-25 |
2006-08-28 |
Alza Corp |
Doseringsform med stigende dosisfrigivelse
|
US5788987A
(en)
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
IT1291652B1
(it)
*
|
1997-04-24 |
1999-01-19 |
Apr Trading Sa |
Composizioni farmaceutiche a copertura terapeutica programmata
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
DE19747261A1
(de)
*
|
1997-10-25 |
1999-04-29 |
Bayer Ag |
Osmotisches Arzneimittelfreisetzungssystem
|
US8524277B2
(en)
|
1998-03-06 |
2013-09-03 |
Alza Corporation |
Extended release dosage form
|
US5945123A
(en)
*
|
1998-04-02 |
1999-08-31 |
K-V Pharmaceutical Company |
Maximizing effectiveness of substances used to improve health and well being
|
KR100827254B1
(ko)
|
1998-06-03 |
2008-05-07 |
알자 코포레이션 |
연장된 약물 치료를 제공하기 위한 방법 및 장치
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
AU5062099A
(en)
*
|
1998-07-21 |
2000-02-14 |
Alpenstock Holdings Limited |
An antilipemic formulation
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
EP1126826B3
(fr)
|
1998-11-02 |
2019-05-15 |
Alkermes Pharma Ireland Limited |
Composition de methylphenidate a liberation modifiee multiparticulaire
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US6387403B1
(en)
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
US6610674B1
(en)
*
|
1999-09-28 |
2003-08-26 |
University Of Pennsylvania |
Method of treating inflammatory conditions with progesterone analogs
|
EP2269587A1
(fr)
|
1999-10-29 |
2011-01-05 |
Euro-Celtique S.A. |
Formulations d'hydrocodone à liberation lente
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
JP4100910B2
(ja)
*
|
1999-12-23 |
2008-06-11 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動の薬物剤形
|
MXPA02006335A
(es)
|
1999-12-23 |
2002-12-13 |
Pfizer Prod Inc |
Forma de dosificacion de farmaco en capas impulsada por hidrogel.
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
AU2002227383B2
(en)
|
2000-10-30 |
2004-07-08 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US20110104214A1
(en)
*
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
MXPA04000209A
(es)
*
|
2001-07-10 |
2005-03-07 |
Teva Pharma |
Sistema de administracion para la administracion de droga de orden cero, bifasica de orden cero, ascendente o descendente.
|
US6863901B2
(en)
*
|
2001-11-30 |
2005-03-08 |
Collegium Pharmaceutical, Inc. |
Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
|
US6827946B2
(en)
*
|
2001-12-05 |
2004-12-07 |
Collegium Pharmaceutical, Inc. |
Compositions containing both sedative and non-sedative antihistamines
|
EP1492509A1
(fr)
*
|
2001-12-18 |
2005-01-05 |
ALZA Corporation |
Forme posologique permettant d'obtenir des modeles d'apport de medicaments variant dans le temps
|
US20040052843A1
(en)
*
|
2001-12-24 |
2004-03-18 |
Lerner E. Itzhak |
Controlled release dosage forms
|
EP2172192A1
(fr)
*
|
2001-12-24 |
2010-04-07 |
Teva Pharmaceutical Industries Ltd. |
Forme de dosage dotée d'un comprimé central d'ingrédient actif insérée dans un corps annulaire comprimé de poudre de matériau granulaire et procédé et outillage pour la produire
|
AU2003234216A1
(en)
*
|
2002-04-29 |
2003-11-17 |
Alza Corporation |
Methods and dosage forms for controlled delivery of oxycodone
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
WO2003101384A2
(fr)
*
|
2002-05-31 |
2003-12-11 |
Alza Corporation |
Formes galeniques et compositions d'administration osmotique de diverses posologies de l'oxycodone
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
WO2004010970A1
(fr)
*
|
2002-07-29 |
2004-02-05 |
Alza Corporation |
Formulations et formes posologiques pour une administration controlee de topiramate
|
CN1684670A
(zh)
*
|
2002-07-29 |
2005-10-19 |
阿尔扎公司 |
用于控制释放帕潘立酮的方法和剂型
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
ES2325209T3
(es)
*
|
2002-07-31 |
2009-08-28 |
Phafag Aktiengesellschaft |
Formulacion farmaceutica y su uso en el tratamiento de enfermedades del oido interno.
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
AU2003299659A1
(en)
|
2002-12-13 |
2004-07-09 |
Durect Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
US8293799B2
(en)
*
|
2003-12-29 |
2012-10-23 |
Osmotica Keresleedelmo és Szolgáltató KFT |
Osmotic device containing a venlafaxine salt and a salt having an ion in common
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
JP2006522016A
(ja)
*
|
2003-01-14 |
2006-09-28 |
アルザ・コーポレーシヨン |
改変された粘度の層を用いる方法および投薬形態物
|
WO2004071497A1
(fr)
*
|
2003-02-11 |
2004-08-26 |
Alza Corporation |
Methodes et formes dosifiees presentant une geometrie de couche modifiee
|
US7632521B2
(en)
*
|
2003-07-15 |
2009-12-15 |
Eurand, Inc. |
Controlled release potassium chloride tablets
|
CA2534920A1
(fr)
*
|
2003-08-06 |
2005-02-24 |
Alza Corporation |
Administration reguliere de topiramate pendant une periode prolongee a formulation de dispersion amelioree
|
EP1658048A2
(fr)
*
|
2003-08-22 |
2006-05-24 |
ALZA Corporation |
Administration progressive de topiramate sur une duree prolongee
|
WO2005020959A2
(fr)
*
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Compositions medicamenteuses et formes pharmaceutiques de topiramate
|
CA2540308C
(fr)
|
2003-09-26 |
2013-08-06 |
Alza Corporation |
Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
|
KR101169614B1
(ko)
|
2003-09-26 |
2012-08-03 |
알자 코포레이션 |
상승한 방출 속도를 나타내는 제어 방출 제제
|
CA2540050A1
(fr)
*
|
2003-09-26 |
2005-04-07 |
Nishit B. Modi |
Formes pharmaceutiques osmotiques pour l'administration controlee d'alprazolame
|
JP5563731B2
(ja)
*
|
2003-09-26 |
2014-07-30 |
アルザ・コーポレーシヨン |
オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
|
US20050163848A1
(en)
*
|
2003-10-31 |
2005-07-28 |
Wong Patrick S. |
Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
|
KR20060123493A
(ko)
*
|
2003-12-23 |
2006-12-01 |
알자 코포레이션 |
제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
MXPA06007510A
(es)
*
|
2003-12-29 |
2009-06-10 |
Johnson & Johnson |
Composiciones de farmaco y formas de dosis novedosas de topiramato.
|
CA2551815A1
(fr)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation |
Compositions medicamenteuses et formes pharmaceutiques
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
WO2006007323A2
(fr)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Formes posologiques pour agents pharmaceutiques exempts d'acides a taux de dissolution et/ou de solubilite bas
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
CN101076248A
(zh)
*
|
2004-12-09 |
2007-11-21 |
塞尔基因公司 |
使用d-苏型哌甲酯的治疗
|
US20060165798A1
(en)
*
|
2005-01-27 |
2006-07-27 |
Edgren David E |
Oral osmotic dosage form having a high flux membrane
|
CA2605180A1
(fr)
*
|
2005-04-19 |
2006-10-26 |
Alza Corporation |
Combinaison de tramadol et de matieres renfermant la gabapentine
|
EP1904030A2
(fr)
*
|
2005-06-29 |
2008-04-02 |
Alza Corporation |
Compositions semi-permeables permettant de reduire le temps de sechage de formes posologiques osmotiques
|
WO2007106111A2
(fr)
*
|
2005-07-01 |
2007-09-20 |
Elan Pharma International Limited |
Compositions nanoparticulaires et a liberation controlee comprenant de la nilvadipine
|
WO2007019393A2
(fr)
*
|
2005-08-04 |
2007-02-15 |
Alza Corporation |
Formes posologiques osmotiques comprenant des membranes semi-permeables formees de melanges polymeres presentant des caracteristiques ameliorees
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
US20070190137A1
(en)
*
|
2005-10-07 |
2007-08-16 |
Reyes Iran |
Osmotic dosage form with controlled release and fast release aspects
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
US20070196487A1
(en)
*
|
2006-02-16 |
2007-08-23 |
Geerke Johan H |
Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
|
ES2378573T3
(es)
|
2006-03-16 |
2012-04-16 |
Tris Pharma, Inc. |
Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
|
TW200815045A
(en)
*
|
2006-06-29 |
2008-04-01 |
Jazz Pharmaceuticals Inc |
Pharmaceutical compositions of ropinirole and methods of use thereof
|
US20110086092A1
(en)
*
|
2006-08-08 |
2011-04-14 |
Accu-Break Technologies, Inc. |
Pharmacuetical tablets containing a plurality of active ingredients
|
JPWO2008084698A1
(ja)
|
2006-12-28 |
2010-04-30 |
アステラス製薬株式会社 |
タクロリムス徐放性医薬組成物
|
US8524749B2
(en)
*
|
2007-02-09 |
2013-09-03 |
Alza Corporation |
Controlled release compositions of tizanidine
|
US20080207593A1
(en)
*
|
2007-02-28 |
2008-08-28 |
Collegium Pharmaceutical, Inc. |
Antihistamine Combination
|
CA2706931C
(fr)
|
2007-12-06 |
2015-05-12 |
Durect Corporation |
Formes posologiques pharmaceutiques orales
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
CN102316730A
(zh)
*
|
2008-05-09 |
2012-01-11 |
天雅瑞药业有限公司 |
用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
|
MX2011000909A
(es)
*
|
2008-07-30 |
2011-02-23 |
Panacea Biotec Ltd |
Composiciones de ramipril de liberacion modificada y usos de las mismas.
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010077925A2
(fr)
|
2008-12-16 |
2010-07-08 |
Teva Pharmaceutical Industries Ltd. |
Système d'administration médicamenteuse d'ordre zéro, administration médicamenteuse biphasique d'ordre zéro, ascendante ou descendante de méthylphénidate
|
US8568793B2
(en)
*
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
EP2478919A4
(fr)
|
2009-09-15 |
2014-04-30 |
Team Academy Of Pharmaceutical Science |
Comprimé à libération contrôlée intégrant une pompe osmotique et son procédé de préparation
|
US20130011477A1
(en)
*
|
2010-03-29 |
2013-01-10 |
Hetero Research Foundation |
Stable Pharmaceutical Composition of Imatinib
|
ES2665467T3
(es)
|
2010-03-29 |
2018-04-25 |
Astellas Pharma Inc. |
Composición farmacéutica de liberación modificada
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
CA2859241C
(fr)
*
|
2012-01-17 |
2019-01-29 |
Croda, Inc. |
Additif de scellement gonflant renfermant un diester de sorbitol
|
DK2884961T3
(en)
|
2012-08-15 |
2019-04-23 |
Tris Pharma Inc |
METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
|
CN105120659A
(zh)
|
2013-03-15 |
2015-12-02 |
度瑞公司 |
用于降低溶解可变性的具有流变改性剂的组合物
|
CA3018328A1
(fr)
|
2014-10-31 |
2016-04-30 |
Purdue Pharma |
Methodes et compositions destinees au traitement du trouble de deficit d'attention
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
SG11201811760VA
(en)
|
2016-07-06 |
2019-01-30 |
Durect Corp |
Oral dosage form with drug composition, barrier layer and drug layer
|
US9707217B1
(en)
|
2017-02-03 |
2017-07-18 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dose-dumping resistant controlled release dosage form
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
KR20200123181A
(ko)
|
2018-02-16 |
2020-10-28 |
에스페리온 테라피유틱스 인코포레이티드 |
뱀페도익산의 지속 방출형 제제
|
ES2909803T3
(es)
|
2018-03-05 |
2022-05-10 |
Amneal Complex Products Res Llc |
Composiciones farmacéuticas programables para la cronoliberación de fármacos
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020181127A1
(fr)
|
2019-03-05 |
2020-09-10 |
Kashiv Biosciences, Llc |
Compositions de méthylphénidate à libération retardée
|
CN114340615A
(zh)
|
2019-08-12 |
2022-04-12 |
麻省理工学院 |
用于施用治疗剂的制品和方法
|
CN114681422B
(zh)
*
|
2020-12-30 |
2023-09-05 |
深圳翰宇药业股份有限公司 |
一种硝苯地平控释片及其制备方法
|